Complex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics

• Published in: European journal of pharmaceutical sciences Vol. 186; p. 106450
• Main Authors: Lu, Dan, Yadav, Rajbharan, Holder, Patrick, Chiang, Eugene, Sanjabi, Shomyseh, Poon, Victor, Bernett, Matthew, Varma, Rajat, Liu, Ke, Leung, Irene, Bogaert, Liz, Desjarlais, John, Shivva, Vittal, Hosseini, Iraj, Ramanujan, Saroja
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-07-2023
• Subjects: Animals; Antineoplastic Agents; Engineered fusion protein; Immunologic Factors; Interleukin-15 - metabolism; Lymphocytes - metabolism; Lymphoproliferative cytokine; Macaca fascicularis - metabolism; Network Pharmacology; Pharmacodynamic (PD)-enhanced TMDD; Quantitative systems pharmacology (QSP) model; Receptors, Interleukin-15; Target-mediated drug disposition (TMDD); Engineered fusion protein; Target-mediated drug disposition (TMDD); Lymphoproliferative cytokine; Quantitative systems pharmacology (QSP) model; Pharmacodynamic (PD)-enhanced TMDD
• ISSN: 0928-0987; 1879-0720
• DOI: 10.1016/j.ejps.2023.106450

•A QSP model quantified the PD-enhanced TMDD of an engineered cytokine in cynos.•The model simultaneously described PK and PD of several lymphocyte subsets.•The model can simulate PK/PD at alternative dosing regimen.•The model will be useful for interpreting clinical data and support regimen optimization.•The model can be adapted for other lymphoproliferative cytokine agonists.
XmAb24306 is a lymphoproliferative interleukin (IL)-15/IL-15 receptor α (IL-15Rα) Fc-fusion protein currently under clinical investigation as an immunotherapeutic agent for cancer treatment. XmAb24306 contains mutations in IL-15 that attenuate its affinity to the heterodimeric IL-15 receptor βγ (IL-15R). We observe substantially prolonged pharmacokinetics (PK) (half-life ∼ 2.5 to 4.5 days) in single- and repeat-dose cynomolgus monkey (cyno) studies compared to wild-type IL-15 (half-life ∼ 1 hour), leading to increased exposure and enhanced and durable expansion of NK cells, CD8+ T cells and CD4–CD8– (double negative [DN]) T cells. Drug clearance varied with dose level and time post-dose, and PK exposure decreased upon repeated dosing, which we attribute to increased target-mediated drug disposition (TMDD) resulting from drug-induced lymphocyte expansion (i.e., pharmacodynamic (PD)-enhanced TMDD). We developed a quantitative systems pharmacology (QSP) model to quantify the complex PKPD behaviors due to the interactions of XmAb24306 with multiple cell types (CD8+, CD4+, DN T cells, and NK cells) in the peripheral blood (PB) and lymphoid tissues. The model, which includes nonspecific drug clearance, binding to and TMDD by IL15R differentially expressed on lymphocyte subsets, and resultant lymphocyte margination/migration out of PB, expansion in lymphoid tissues, and redistribution to the blood, successfully describes the systemic PK and lymphocyte kinetics observed in the cyno studies. Results suggest that after 3 doses of every-two-week (Q2W) doses up to 70 days, the relative contributions of each elimination pathway to XmAb24306 clearance are: DN T cells > NK cells > CD8+ T cells > nonspecific clearance > CD4+ T cells. Modeling suggests that observed cellular expansion in blood results from the influx of cells expanded by the drug in lymphoid tissues. The model is used to predict lymphoid tissue expansion and to simulate PK-PD for different dose regimens. Thus, the model provides insight into the mechanisms underlying the observed PK-PD behavior of an engineered cytokine and can serve as a framework for the rapid integration and analysis of data that emerges from ongoing clinical studies in cancer patients as single-agent or given in combination.
[Display omitted]